- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Colon Cancer, Endocrine Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Metastatic Cancer, Multiple Myeloma, Parathyroid Neoplasms, Renal Cancer, Thyroid Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Non-Small Cell Lung Cancer
- Interventions
- denosumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 12
- States / cities
- Encinitas, California • New Haven, Connecticut • Salisbury, Maryland + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 137
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Vaginal Cancer
- Interventions
- QOL
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Thromboembolism, Vaginal Cancer, Vulvar Cancer
- Interventions
- fondaparinux sodium
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Upland, Pennsylvania
- Conditions
- Ovarian Cancer
- Interventions
- Imatinib Mesylate, Docetaxel
- Drug
- Lead sponsor
- Daniela Matei, MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 9
- States / cities
- Galesburg, Illinois • Elkhart, Indiana • Evansville, Indiana + 6 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- DFF332, RAD001, PDR001, NIR178
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Duarte, California • Boston, Massachusetts • St Louis, Missouri + 2 more
- Conditions
- Solid Tumors, Ovarian Cancer, Endometrial Cancer
- Interventions
- ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 2 more
- Conditions
- Melanoma, Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, T-Cell, Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-3512676
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 31
- States / cities
- Berkely, California • Gilroy, California • Hollister, California + 23 more
- Conditions
- Surgical Site Infection, Surgical Complication, Gynecologic Cancer
- Interventions
- Diagnosed with Surgical Site Infection
- Other
- Lead sponsor
- WellSpan Health
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 778 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- York, Pennsylvania
- Conditions
- Ovary Cancer, Endometrial Cancer
- Interventions
- Educational videos, Survey
- Behavioral
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer
- Interventions
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
- Genetic
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2037
- U.S. locations
- 9
- States / cities
- Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more
- Conditions
- Urinary Retention
- Interventions
- Early removal of urinary catheter postoperatively, Late removal of urinary catheter postoperatively
- Other
- Lead sponsor
- WellSpan Health
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- York, Pennsylvania
- Conditions
- Epithelial Ovarian Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma
- Interventions
- ITIL-306
- Biological
- Lead sponsor
- Instil Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • New York, New York
- Conditions
- Gynecologic Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Surgery, Treatment Adherence, Quality of Life
- Interventions
- Unimodal, Trimodal
- Other
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cancer, Cancer-Related Condition, Infertility
- Interventions
- Testicular tissue cryopreservation
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 0 Years to 17 Years · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
- Interventions
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more
- Conditions
- Advanced Malignant Tumors
- Interventions
- BMS-986488, Adagrasib, Cetuximab, Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 437 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Hackensack, New Jersey • Allentown, Pennsylvania • Germantown, Tennessee + 1 more
- Conditions
- Upper Tract Urothelial Carcinoma
- Interventions
- 5-Aminolevulinic acid Hydrochloride (Gliolan®)
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
- Interventions
- galinpepimut-S, pembrolizumab, Montanide, GM-CSF
- Biological · Other
- Lead sponsor
- Sellas Life Sciences Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 12
- States / cities
- Santa Rosa, California • Whittier, California • Miami, Florida + 9 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ASP1951, pembrolizumab
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Sacramento, California • Gainesville, Florida + 15 more
- Conditions
- Solid Tumor, Lymphoma
- Interventions
- TTX-030, Pembrolizumab, Gemcitabine, nab paclitaxel
- Drug
- Lead sponsor
- Trishula Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 16
- States / cities
- Orange, California • Sacramento, California • San Francisco, California + 12 more
- Conditions
- Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer, Bladder Cancer, Ovarian Cancer, Abdominal Surgery Complications
- Interventions
- Multidisciplinary Prehabilitation Program
- Behavioral
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
- Interventions
- Systemic therapy, StrataNGS
- Other · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
- Interventions
- COM701 in combination with BMS-986207 and nivolumab.
- Drug
- Lead sponsor
- Compugen Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 6 more
- Conditions
- Oncology, Interventional Radiology, Liver Carcinoma, Renal Carcinoma, Biopsy
- Interventions
- Augmented Reality Guided Biopsy, Ultrasound Guided Biopsy
- Device
- Lead sponsor
- MediView XR, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • New York, New York